Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros' clinical-stage MASP-3 inhibitor zaltenibart (OMS906)

Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros' clinical-stage MASP-3 inhibitor zaltenibart (OMS906) — alphai